Raras
Buscar doenças, sintomas, genes...
Síndrome de mioclonia-distonia
ORPHA:36899CID-10 · G24.1CID-11 · 8A02.11PCDT · SUSDOENÇA RARA

A Síndrome de Mioclonia-Distonia (SMD) é uma condição rara que afeta os movimentos, caracterizada por distonia leve a moderada e também espasmos mioclônicos rápidos como um raio.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Síndrome de Mioclonia-Distonia (SMD) é uma condição rara que afeta os movimentos, caracterizada por distonia leve a moderada e também espasmos mioclônicos rápidos como um raio.

Pesquisas ativas
1 ensaio
4 total registrados no ClinicalTrials.gov
Publicações científicas
104 artigos
Último publicado: 2026
Medicamentos
1 registrados
ZONISAMIDE

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
ZONISAMIDE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Adolescent
+ adult, childhood
🏥
SUS: Cobertura parcialScore: 45%
PCDT disponívelCID-10: G24.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
9 sintomas
🧠
Neurológico
8 sintomas

+ 8 sintomas em outras categorias

Características mais comuns

90%prev.
Mioclonia de membro
Muito frequente (99-80%)
90%prev.
Mioclonia espinhal
Muito frequente (99-80%)
90%prev.
Distonia
Muito frequente (99-80%)
90%prev.
Mioclonias
Muito frequente (99-80%)
55%prev.
Cãibra do escrivão
Frequente (79-30%)
55%prev.
Comportamentos compulsivos
Frequente (79-30%)
25sintomas
Muito frequente (4)
Frequente (7)
Sem dados (14)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 25 características clínicas mais associadas, ordenadas por frequência.

Mioclonia de membroLimb myoclonus
Muito frequente (99-80%)90%
Mioclonia espinhalSpinal myoclonus
Muito frequente (99-80%)90%
DistoniaDystonia
Muito frequente (99-80%)90%
MiocloniasMyoclonus
Muito frequente (99-80%)90%
Cãibra do escrivãoWriter's cramp
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico104PubMed
Últimos 10 anos55publicações
Pico20258 papers
Linha do tempo
2026Hoje · 2026🧪 2007Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

5 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Not applicable.

SGCEEpsilon-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeletonCell projection, dendriteGolgi apparatus

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Dystonia 11, myoclonic

A myoclonic dystonia. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT11 is characterized by involuntary lightning jerks and dystonic movements and postures alleviated by alcohol. Inheritance is autosomal dominant. The age of onset, pattern of body involvement, presence of myoclonus and response to alcohol are all variable.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
121.7 TPM
Nervo tibial
89.5 TPM
Aorta
82.0 TPM
Cervix Ectocervix
78.5 TPM
Fallopian Tube
75.7 TPM
OUTRAS DOENÇAS (2)
myoclonic dystonia 11myoclonus-dystonia syndrome
HGNC:10808UniProt:O43556
DYT15Role in the phenotype ofDesconhecido
LOCALIZAÇÃO

HGNC:31376
DRD2D(2) dopamine receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (1)
Dopamine receptors
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
81.4 TPM
Brain Nucleus accumbens basal ganglia
51.9 TPM
Brain Putamen basal ganglia
45.7 TPM
Brain Caudate basal ganglia
40.7 TPM
Glândula salivar
11.4 TPM
OUTRAS DOENÇAS (1)
myoclonus-dystonia syndrome
HGNC:3023UniProt:P14416
TOR1ATorsin-1ACandidate gene tested inTolerante
FUNÇÃO

Protein with chaperone functions important for the control of protein folding, processing, stability and localization as well as for the reduction of misfolded protein aggregates. Involved in the regulation of synaptic vesicle recycling, controls STON2 protein stability in collaboration with the COP9 signalosome complex (CSN). In the nucleus, may link the cytoskeleton with the nuclear envelope, this mechanism seems to be crucial for the control of nuclear polarity, cell movement and, specificall

LOCALIZAÇÃO

Endoplasmic reticulum lumenNucleus membraneCell projection, growth coneCytoplasmic vesicle membraneCytoplasmic vesicle, secretory vesicleCytoplasmic vesicle, secretory vesicle, synaptic vesicleCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Cargo recognition for clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Dystonia 1, torsion, autosomal dominant

A primary torsion dystonia, and the most common and severe form. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. Dystonia type 1 is characterized by involuntary, repetitive, sustained muscle contractions or postures involving one or more sites of the body, in the absence of other neurological symptoms. Typically, symptoms develop first in an arm or leg in middle to late childhood and progress in approximately 30% of patients to other body regions (generalized dystonia) within about five years. 'Torsion' refers to the twisting nature of body movements observed in DYT1, often affecting the trunk. Distribution and severity of symptoms vary widely between affected individuals, ranging from mild focal dystonia to severe generalized dystonia, even within families.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
47.1 TPM
Útero
27.4 TPM
Aorta
26.7 TPM
Linfócitos
26.6 TPM
Artéria tibial
25.9 TPM
OUTRAS DOENÇAS (3)
early-onset generalized limb-onset dystoniaarthrogryposis multiplex congenita 5myoclonus-dystonia syndrome
HGNC:3098UniProt:O14656
KCTD17BTB/POZ domain-containing protein KCTD17Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Substrate-adapter for CUL3-RING ubiquitin ligase complexes which mediates the ubiquitination and subsequent proteasomal degradation of TCHP, a protein involved in ciliogenesis down-regulation. Thereby, positively regulates ciliogenesis, playing a crucial role in the initial steps of axoneme extension (PubMed:25270598). May also play a role in endoplasmic reticulum calcium ion homeostasis (PubMed:25983243)

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Dystonia 26, myoclonic

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT26 is an autosomal dominant, progressive disorder characterized by a combination of non-epileptic myoclonic jerks and dystonia. Affected individuals manifest myoclonic jerks in the upper limbs during the first or second decade of life, and later develop dystonia with predominant involvement of the craniocervical regions and sometimes the trunk and/or lower limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Caudate basal ganglia
112.4 TPM
Brain Putamen basal ganglia
103.4 TPM
Testículo
86.7 TPM
Brain Nucleus accumbens basal ganglia
78.9 TPM
Brain Frontal Cortex BA9
67.5 TPM
OUTRAS DOENÇAS (2)
myoclonic dystonia 26myoclonus-dystonia syndrome
HGNC:25705UniProt:Q8N5Z5

Medicamentos e terapias

ZONISAMIDEPhase 3

Mecanismo: Sodium channel alpha subunit blocker

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

127 variantes patogênicas registradas no ClinVar.

🧬 KCTD17: NM_001282684.2(KCTD17):c.190-58G>A ()
🧬 KCTD17: NM_001282684.2(KCTD17):c.487-1G>T ()
🧬 KCTD17: NM_001282684.2(KCTD17):c.760C>A (p.Pro254Thr) ()
🧬 KCTD17: NM_001282684.2(KCTD17):c.487-1G>C ()
🧬 KCTD17: NM_001282684.2(KCTD17):c.842G>C (p.Arg281Pro) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2 variantes classificadas pelo ClinVar.

1
1
Patogênica (50.0%)
VUS (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
CASD1: NM_003919.3(SGCE):c.551T>C (p.Leu184Pro) [Pathogenic/Likely pathogenic]
CASD1: NM_003919.3(SGCE):c.677T>A (p.Val226Asp) [Uncertain significance]

Vias biológicas (Reactome)

3 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 21
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 4 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome de mioclonia-distonia

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

4 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
56 papers (10 anos)
#1

Intrafamilial variability of myoclonic dystonia in a large French family carrying a novel SGCE variant.

European journal of medical genetics2026 Mar 02

Myoclonus-dystonia syndrome (MDS) is an autosomal dominant movement disorder most caused by pathogenic variants in SGCE, an imprinted gene subject to maternal silencing. While numerous pathogenic variants have been reported, the extent and determinants of intrafamilial variability remain incompletely understood. We investigated a large French family in which ten individuals across three generations presented with myoclonic jerks, dystonia, or combined phenotypes. Trio whole-exome sequencing performed in the proband, her affected brother, and her affected father identified a heterozygous SGCE variant, NM_003919.3:c.406T > G, predicting a p.Cys136Gly substitution in a highly conserved cysteine-rich extracellular domain of ε-sarcoglycan. The variant segregated with disease in all clinically affected individuals for whom DNA was available and was absent from population databases. The phenotypic spectrum ranged from mild, stress-induced myoclonus in females to early-onset myoclonus with cervical dystonia and alcohol responsiveness in males, consistent with imprinting effects and sex-dependent modifiers. Variant interpretation using ACMG/AMP criteria (PM1, PM2, PM5, PP1-strong, PP2, PP3) supports a pathogenic classification. This previously unreported SGCE missense variant expands the mutational spectrum of MDS and further illustrates the substantial intrafamilial variability of SGCE-related disease.

#2

Intrafamilial variability of myoclonic dystonia in a large French family carrying a novel SGCE variant.

European journal of medical genetics2026 Mar

Myoclonus-dystonia syndrome (MDS) is an autosomal dominant movement disorder most caused by pathogenic variants in SGCE, an imprinted gene subject to maternal silencing. While numerous pathogenic variants have been reported, the extent and determinants of intrafamilial variability remain incompletely understood. We investigated a large French family in which ten individuals across three generations presented with myoclonic jerks, dystonia, or combined phenotypes. Trio whole-exome sequencing performed in the proband, her affected brother, and her affected father identified a heterozygous SGCE variant, NM_003919.3:c.406T > G, predicting a p.Cys136Gly substitution in a highly conserved cysteine-rich extracellular domain of ε-sarcoglycan. The variant segregated with disease in all clinically affected individuals for whom DNA was available and was absent from population databases. The phenotypic spectrum ranged from mild, stress-induced myoclonus in females to early-onset myoclonus with cervical dystonia and alcohol responsiveness in males, consistent with imprinting effects and sex-dependent modifiers. Variant interpretation using ACMG/AMP criteria (PM1, PM2, PM5, PP1-strong, PP2, PP3) supports a pathogenic classification. This previously unreported SGCE missense variant expands the mutational spectrum of MDS and further illustrates the substantial intrafamilial variability of SGCE-related disease.

#3

Long-Term Efficacy of Bilateral Globus Pallidus Internus Deep Brain Stimulation in Myoclonus-Dystonia Associated with KCNN2 Gene Mutation: A Case Study.

International journal of molecular sciences2025 Aug 10

Dystonia-myoclonus syndrome is a rare neurological condition characterized by involuntary muscle contractions and myoclonic jerks, significantly impairing daily functioning. Pharmacological management is often ineffective, prompting consideration of alternative therapeutic interventions such as deep brain stimulation (DBS). This report describes a novel clinical case involving a 38-year-old female with severe dystonic and myoclonic symptoms associated with a pathogenic mutation in the KCNN2 gene (DYT34). Bilateral DBS targeting the internal segment of the globus pallidus (GPi) resulted in marked and sustained symptom improvement, notably reducing dystonic posturing and myoclonic movements over the 24-month follow-up period. Neuropsychological and neurologopedic assessments revealed no adverse effects on cognition or speech. This represents the first sufficient effect of GPi-DBS in a patient with a genetically confirmed KCNN2 mutation, highlighting its potential efficacy and underscoring the need for genetic testing in patients presenting with dystonia-myoclonus syndromes.

#4

Developmental and Epileptic Encephalopathy as a Novel Clinical Hallmark of SCA21.

Neuropediatrics2025 Dec

Spinocerebellar ataxia-21 (SCA21) is an autosomal dominant neurodegenerative disorder due to pathogenic variants of the TMEM240 gene. Its clinical presentation usually includes slowly progressive cerebellar ataxia, myoclonus-dystonia syndrome, cognitive impairment, and behavioral problems. Here, we reported the first patient with SCA21 presenting with a developmental and epileptic encephalopathy with seizure onset during late childhood, a seizure semeiology including atonic, clonic, myoclonic seizures, and absences with eyelid myoclonia and an EEG pattern characterized by diffuse spike and wave discharges. Epilepsy was associated with a progressive motor deterioration (the International Cooperative Ataxia Rating Scale-ICARS Total Ataxia score switched from 23/100 to 35/100 over a period of 2 years), a worsening of a preexisting tremor, and a disabling drowsiness. Nonverbal measure of intellectual functioning revealed a moderate intellectual disability (Leiter-R: brief IQ 40; fluid reasoning 52). The epileptogenic mechanisms involving TMEM240 might be correlated with disinhibition of excitotoxic networks due to the loss of Purkinje cells in the cerebellum, but also damage in neuronal bioenergetic pathways and synaptic vesicular trafficking within cortico-cerebellar and thalamo-cerebellar circuits.

#5

Developmental variability in paediatric SGCE-related myoclonus dystonia syndrome.

Developmental medicine and child neurology2025 Jun

This commentary is on the original article by De Francesch et al. on pages 740–749 of this issue.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC66 artigos no totalmostrando 54

2026

Intrafamilial variability of myoclonic dystonia in a large French family carrying a novel SGCE variant.

European journal of medical genetics
2025

Infantile Epsilon-Sarcoglycan (SGCE) Myoclonus-Dystonia: Diagnostic Pitfalls and Poor Response to Pharmacologic Treatment.

Cureus
2025

Long-Term Efficacy of Bilateral Globus Pallidus Internus Deep Brain Stimulation in Myoclonus-Dystonia Associated with KCNN2 Gene Mutation: A Case Study.

International journal of molecular sciences
2025

Developmental and Epileptic Encephalopathy as a Novel Clinical Hallmark of SCA21.

Neuropediatrics
2025

Approach to Myoclonus Dystonia Syndrome: A European Reference Network Survey.

Movement disorders clinical practice
2025

Myoclonic status epilepticus with dystonia-like symptoms in patients with dementia: Report of two cases.

Epilepsy &amp; behavior reports
2025

Developmental variability in paediatric SGCE-related myoclonus dystonia syndrome.

Developmental medicine and child neurology
2025

Sodium Oxybate-Treated Familial Myoclonus-Dystonia Syndrome Due to Novel SGCE Variant.

American journal of medical genetics. Part A
2025

Natural history of SGCE-associated myoclonus dystonia in children and adolescents.

Developmental medicine and child neurology
2024

Bilateral globus pallidus internus-deep brain stimulation in a 5-year-old boy with SGCE-related myoclonus dystonia syndrome.

Pediatric investigation
2024

Myoclonus-Dystonia Plus Syndrome With Early-Onset Multiple Cerebral Cavernous Malformation Type 1 and Growth Hormone Deficiency Associated With Novel 7q21.13-q21.3 Deletion: A Pediatric Case Report.

Cureus
2023

Improvement in Myoclonus-Dystonia Syndrome during Treatment with Gonadotropin-Releasing Hormone Agonist.

Movement disorders clinical practice
2023

The expanding genetic landscape of myoclonus-dystonia syndrome: YY1 and ATP1A3 are added to the list.

Parkinsonism &amp; related disorders
2023

Deep Brain Stimulation for an Unusual Presentation of Myoclonus Dystonia Associated with Russell-Silver Syndrome.

Tremor and other hyperkinetic movements (New York, N.Y.)
2023

Two-Generation Epsilon-Sarcoglycan Gene (SGCE) Mutation-Associated Myoclonus-Dystonia (DYT-SGCE) Misdiagnosed as Tourette's Syndrome: A Case Series.

Cureus
2023

Case report: Unilateral GPi DBS in secondary myoclonus-dystonia syndrome after acute disseminated encephalomyelitis.

Frontiers in neurology
2023

Translating Genetic Discovery into a Mechanistic Understanding of Pediatric Movement Disorders: Lessons from Genetic Dystonias and Related Disorders.

Advanced genetics (Hoboken, N.J.)
2023

Perampanel as a novel treatment for subcortical myoclonus in myoclonus-dystonia syndrome.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2022

Pearls & Oy-sters: SCA21 Due to TMEM240 Variation Presenting as Myoclonus Dystonia Syndrome.

Neurology
2022

Effect of the R126C mutation on the structure and function of the glucose transporter GLUT1: A molecular dynamics simulation study.

Journal of molecular graphics &amp; modelling
2022

A Case Report of Siblings with Dystonia: A Potential Link Between DYT11 Mutation and Platelet Dysfunction.

Neurology India
2022

KCNN2 Mutation in Pediatric Tremor Myoclonus Dystonia Syndrome with Electrophysiological Evaluation.

Tremor and other hyperkinetic movements (New York, N.Y.)
2022

Bilateral Pallidal Stimulation in a Family With Myoclonus Dystonia Syndrome Due to a Mutation in the Sarcoglycan Gene.

Neuromodulation : journal of the International Neuromodulation Society
2021

Mutation in ε-Sarcoglycan Induces a Myoclonus-Dystonia Syndrome-Like Movement Disorder in Mice.

Neuroscience bulletin
2021

Successful Unilateral Surgical Approach to Internal Globus Pallidus and Ventral Intermediate Nucleus of the Thalamus in 3 Cases of Myoclonus-Dystonia Syndrome.

Stereotactic and functional neurosurgery
2020

Delineating the motor phenotype of SGCE-myoclonus dystonia syndrome.

Parkinsonism &amp; related disorders
2020

KCTD17-related myoclonus-dystonia syndrome: clinical and electrophysiological findings of a patient with atypical late onset.

Parkinsonism &amp; related disorders
2020

[Clinical and genetic analysis of childhood-onset myoclonus dystonia syndrome caused by SGCE variants].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2020

Clinical phenotype heterogeneity in a family with ε-sarcoglycan gene mutation.

Neurologia i neurochirurgia polska
2021

Deep brain stimulation for myoclonus dystonia syndrome: a meta-analysis with individual patient data.

Neurosurgical review
2019

A South African family with myoclonus-dystonia syndrome with a novel mutation in the SGCE gene responding to deep brain stimulation.

Parkinsonism &amp; related disorders
2019

A Novel SGCE Nonsense Variant Associated With Marked Intrafamilial Variability in a Turkish Family With Myoclonus-Dystonia.

Movement disorders clinical practice
2019

A retrospective analysis of the prevalence of imprinting disorders in Estonia from 1998 to 2016.

European journal of human genetics : EJHG
2019

Screening for SGCE mutations in Moroccan sporadic patients with Myoclonus-Dystonia syndrome.

Neuroscience letters
2019

Adult-Onset Myoclonus-Dystonia Syndrome Preceding Characteristic Facial Myoclonus in Indian ADCY5-related Dyskinesia.

Movement disorders clinical practice
2019

Thalamus Stimulation for Myoclonus Dystonia Syndrome: Five Cases and Long-Term Follow-up.

World neurosurgery
2018

Delineating cerebellar mechanisms in DYT11 myoclonus-dystonia.

Movement disorders : official journal of the Movement Disorder Society
2018

Frameless robot-assisted pallidal deep brain stimulation surgery in pediatric patients with movement disorders: precision and short-term clinical results.

Journal of neurosurgery. Pediatrics
2018

Novel SGCE mutation in a patient with myoclonus-dystonia syndrome - Diagnostic delay of more than 40 years.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2017

[Parasomnia and paroxysmal dyskinesia].

Der Nervenarzt
2017

Psychiatric symptoms in myoclonus-dystonia syndrome are just concomitant features regardless of the SGCE gene mutation.

Parkinsonism &amp; related disorders
2017

Deep brain stimulation for myoclonus-dystonia syndrome with double mutations in DYT1 and DYT11.

Scientific reports
2017

Role of major and brain-specific Sgce isoforms in the pathogenesis of myoclonus-dystonia syndrome.

Neurobiology of disease
2016

Bilateral pallidal deep brain stimulation in myoclonus-dystonia: our experience in three cases and their follow-up.

Acta neurochirurgica
2016

Speech-activated Myoclonus Mimicking Stuttering in a Patient with Myoclonus-Dystonia Syndrome.

Tremor and other hyperkinetic movements (New York, N.Y.)
2016

Deep brain stimulation for the treatment of hyperkinetic movement disorders.

Expert review of neurotherapeutics
2016

Early deep brain stimulation in patients with myoclonus-dystonia syndrome.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2017

Genetic Aspects of Myoclonus-Dystonia Syndrome (MDS).

Molecular neurobiology
2016

Progression of neuropsychiatric and cognitive features due to exons 2 to 5 deletion in the epsilon-sarcoglycan gene: a case report.

Neurocase
2015

The first disease connection for Cav2.2 channels.

General physiology and biophysics
2015

Steroid-responsive autoimmune encephalopathy associated with autoimmune thyroiditis (SREAT) presenting with myoclonus-dystonia syndrome.

Journal of the neurological sciences
2015

Japanese familial case of myoclonus-dystonia syndrome with a splicing mutation in SGCE.

Pediatrics international : official journal of the Japan Pediatric Society
2014

Myoclonus-dystonia syndrome: case report.

Northern clinics of Istanbul
2015

Sarcoglycans and gaba(a) receptors in rat central nervous system: an immunohistochemical study.

Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia
Ver todos os 66 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome de mioclonia-distonia.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome de mioclonia-distonia

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Intrafamilial variability of myoclonic dystonia in a large French family carrying a novel SGCE variant.
    European journal of medical genetics· 2026· PMID 41780719mais citado
  2. Intrafamilial variability of myoclonic dystonia in a large French family carrying a novel SGCE variant.
    European journal of medical genetics· 2026· PMID 41747888mais citado
  3. Long-Term Efficacy of Bilateral Globus Pallidus Internus Deep Brain Stimulation in Myoclonus-Dystonia Associated with KCNN2 Gene Mutation: A Case Study.
    International journal of molecular sciences· 2025· PMID 40869056mais citado
  4. Developmental and Epileptic Encephalopathy as a Novel Clinical Hallmark of SCA21.
    Neuropediatrics· 2025· PMID 40602760mais citado
  5. Developmental variability in paediatric SGCE-related myoclonus dystonia syndrome.
    Developmental medicine and child neurology· 2025· PMID 39826107mais citado
  6. Beyond SGCE: expanding the clinical and molecular spectrum of KCTD17- and KCNN2-related myoclonus-dystonia.
    Front Neurol· 2026· PMID 41982418recente
  7. Infantile Epsilon-Sarcoglycan (SGCE) Myoclonus-Dystonia: Diagnostic Pitfalls and Poor Response to Pharmacologic Treatment.
    Cureus· 2025· PMID 41613668recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:36899(Orphanet)
  2. MONDO:0000903(MONDO)
  3. Distonia e Espasticidade(PCDT · Ministério da Saúde)
  4. GARD:7139(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q3710440(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome de mioclonia-distonia
Compêndio · Raras BR

Síndrome de mioclonia-distonia

ORPHA:36899 · MONDO:0000903
🇧🇷 Brasil SUS
Geral
Prevalência
1-9 / 1 000 000
Herança
Autosomal dominant, Not applicable
CID-10
G24.1 · Distonia familiar idiopática
CID-11
Ensaios
1 ativos
Medicamentos
1 registrados
Início
Adolescent, Adult, Childhood
Prevalência
0.0 (Europe)
MedGen
UMLS
C1834570
Repurposing
1 candidato
procyclidineacetylcholine receptor antagonist
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades